BEGIN:VCALENDAR
PRODID:-//AT Content Types//AT Event//EN
VERSION:1.0
BEGIN:VEVENT
DTSTART:20090126T080000Z
DTEND:20090128T080000Z
DCREATED:20080731T090410Z
UID:ATEvent-c807b62945c7fce6b8c6b6abc81377d9
SEQUENCE:0
LAST-MODIFIED:20080731T100758Z
SUMMARY:CHI’S BIOMARKER ASSAY DEVELOPMENT
DESCRIPTION:The increasing importance of biomarkers in the drug discov
 ery process calls for a comprehensive biomarker strategy that must inc
 lude assay development and validation. CHI’s Inaugural Biomarker Ass
 ay Development meeting addresses “fit-for-purpose” method developm
 ent\, spanning pre-clinical and clinical drug development\, as well as
  diagnostics. The meeting will provide an overview of novel assay plat
 forms for genomic and proteomic analysis\, as well as multiplexed assa
 ys\, flow cytometry\, and more. It will also discuss the pros and cons
  of developing the assay in-house vs. adopting off-the-shelf solutions
 /kits vs. outsourcing. And finally\, since the meeting is co-located w
 ith the Translational Cancer Medicine meeting\, it will also focus on 
 biomarker assays in oncology.
LOCATION:The Westin San Diego
PRIORITY:3
TRANSP:0
END:VEVENT
END:VCALENDAR